The effect of thiazolidinediones on lipoprotein metabolism: A double blind randomised placebo controlled trial using stable isotopes to investigate the effect of pioglitazone, rosiglitazone and placebo on lipoprotein(apolipoprotein B100, VLDL, IDL and LDL) metabolism.

Abstract

+/- 0.82) with well controlled diabetes (mean HbAlc7.02% +/- 0.15), and lipids (mean total cholesterol 4.91mmol/l +/- 0.17, mean HDL cholesterol 1.21mmol/l +/- 0.06, median triglyceride 1.61 mmol/1 [1.22, 1.97]) at baseline. Following treatment there was a significant reduction in HbAlc in the rosiglitazone (-0.48%, p < 0.05) and the pioglitazone group (-0.71%, p < 0.05), a significant reduction in free fatty acids in both active treatment groups but no change in any other lipid variable. There was a significant reduction in VLDL apo B absolute secretion rate in the rosiglitazone group (-2.19nig/kg/day, p = 0.017) but no change in catabolic rate in any group and no change in IDL or LDL metabolism. These results were not as expected and reasons for this are discussed